- Current Drug Therapies for Non-Small Cell Lung Cancer
- Harvard study: studied healthy eating can prolong life and reduce risks of death!
- Massachusetts: Prisoners may get a reduced sentence by donating organs
- Smoking seriously hurts human brains
- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
EU approves AstraZeneca’s COVID-19 vaccine as booster shot
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
EU approves AstraZeneca’s COVID-19 vaccine as booster shot.
On May 23, British/Swedish multinational pharmaceutical company AstraZeneca said that its COVID-19 vaccine Vaxzevria has been approved by the European Medicines Agency (EMA) as a booster vaccine for adults.
Last Thursday, AstraZeneca’s COVID-19 vaccine booster (clinical trial data) received a positive assessment from the European Committee for Medicinal Products for Human Use (CHMP).
AstraZeneca said in a statement on Monday that the company’s COVID-19 vaccine can be used as a booster shot for the first two doses of the Vaxzevria COVID-19 vaccine, as well as other messenger ribonucleic acid (mRNA) produced by companies such as Pfizer/BioNTech or Moderna. A booster shot of the COVID-19 vaccine.
The European Medicines Agency concluded that there was “substantial evidence” of an enhanced immune response following the administration of the Vaxzevria vaccine co-developed with the Oxford conference as a third booster dose, the statement said.
Despite a 40% drop in sales in Europe, where the outbreak is under control following the vaccination, AstraZeneca announced last month that sales of Vaxzevria quadrupled to US$1.15 billion in the first quarter. .
But AstraZeneca also warned in April that COVID-19 revenue, including Vaxzevria, would decline this year as the health crisis subsides.
Vaxzevria is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. COVID-19 is caused by SARS-CoV-2 virus.
Vaxzevria is made up of another virus (of the adenovirus family) that has been modified to contain the gene for making a protein from SARS-CoV-2.
Vaxzevria does not contain the virus itself and cannot cause COVID-19.
(source:internet, reference only)